What Electra Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 4 | 4 |
| Sells | 0 | 0 |
| Total trades | 16 | 16 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 14,630,619 | 14,630,619 |
| Disposed | 0 | 0 |
| Net activity | +14,630,619 | +14,630,619 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Orbimed Advisors Llc | Director | Sep 21 | Open-market buy · P | +1,000,000 | $15.00 | +$15M | 1,758,279 |
| Orbimed Advisors Llc | Director | Sep 21 | Derivative Conversion · C | +758,279 | — | — | 758,279 |
| Orbimed Advisors Llc | Director | Sep 21 | Open-market buy · P | +333,333 | $15.00 | +$5M | 5,126,891 |
| Orbimed Advisors Llc | Director | Sep 21 | Derivative Conversion · C | +1,703,314 | — | — | 4,793,558 |
| Orbimed Advisors Llc | Director | Sep 21 | Derivative Conversion · C | +1,087,934 | — | — | 3,090,244 |
| Orbimed Advisors Llc | Director | Sep 21 | Derivative Conversion · C | +2,002,310 | — | — | 2,002,310 |
| Gordon Carl L | Director | Sep 21 | Open-market buy · P | +1,000,000 | $15.00 | +$15M | 1,758,279 |
| Gordon Carl L | Director | Sep 21 | Derivative Conversion · C | +758,279 | — | — | 758,279 |
| Gordon Carl L | Director | Sep 21 | Open-market buy · P | +333,333 | $15.00 | +$5M | 5,126,891 |
| Gordon Carl L | Director | Sep 21 | Derivative Conversion · C | +1,703,314 | — | — | 4,793,558 |
| Gordon Carl L | Director | Sep 21 | Derivative Conversion · C | +1,087,934 | — | — | 3,090,244 |
| Gordon Carl L | Director | Sep 21 | Derivative Conversion · C | +2,002,310 | — | — | 2,002,310 |
| Dong Quehuong (Kathy) | President & CEO | Sep 21 | Derivative Conversion · C | +455,484 | — | — | 455,484 |
| Koe Gary S. | Chief Technical Officer | Sep 21 | Derivative Conversion · C | +63,656 | — | — | 63,656 |
| Stagliano Nancy | Director | Sep 21 | Derivative Conversion · C | +255,635 | — | — | 255,635 |
| Parry Graham | Chief Scientific Officer | Sep 21 | Derivative Conversion · C | +85,504 | — | — | 85,504 |
Loading...
